/ Lupin Receives FDA Nod For Generic Ancobon Capsules ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Monday, 10 July 2017


Lupin Limited on Monday has received final approval for its Flucytosine Capsules USP, 250 mg and 500 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Valeant Pharmaceuticals International Inc’s Ancobon Capsules, 250 mg and 500 mg. 

Lupin’s Flucytosine Capsules USP, 250 mg and 500 mg are AB rated generic equivalent of Valeant Pharmaceuticals International Inc’s Ancobon Capsules, 250 mg and 500 mg.

Flucytosine Capsules USP, 250 mg and 500 mg are indicated for the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus.

Ancobon capsules had US sales of USD 46.6 million.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 

0 comments: